EIF2AK3 and neoplasm: Of 7 evaluable EP KPC tumours (for example, those that were collected 4 h after the final dose, when RAS signalling is suppressed in naive tumours), 6 tumours (86%) continued to show full inhibition of pERK expression (Fig. 5l), thereby excluding several classes of mechanisms that reactivate RAS–MAPK signalling.